Market Overview

Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate

Share:
Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate
Related CARA
Cantor Fitzgerald's 7 Buys For 7 Biotechs
The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Cara Therapeutics Inc (NASDAQ: CARA), a biotech company developing non-opioid pain relief drugs, has earned a bullish review from Jefferies. 

The Analyst

Analyst Matthew Andrews initiated coverage of Cara with a Buy rating and $30 price target.

The Thesis

Cara's lead program is intravenous Korsuva, which is being tested in chronic kidney disease on hemodialysis-associated pruritis, or CKD-HD-aP, Andrews said in the initiation note. (See his track record here.)

The drug has a promising opportunity given that 180,000 patients in the U.S. suffer from the disease and there is no FDA-approved drug, the analyst said. 

Jefferies estimates peak penetration for Korsuva at 27 percent and peak-adjusted U.S. sales of $573 million.

The CR845 Phase 2/3 study for Korsuva met its primary endpoint by reducing the Worst Itch-Numeric Rating Scale, or WI-NRS, by 3.8 points at Week 8 from the baseline relative to a placebo, Andrew said. 

Based on the data, the candidate was granted breakthrough therapy designation.

Andrews forecast a high likelihood of success in two similar Phase 3 U.S. and global studies initiated in January and December.

The top-line data from the Phase 3 studies, due in mid-2019, is likely to be Cara's next key catalyst, the analyst said. 

A Phase 2/3 study of IV CR845 showed statistically significant pain relief with reduced opioid-related side-effects in post-operative acute pain, according to Jefferies. 

The Price Action

Cara shares have jumped about 70 percent year-to-date.

The shares were rallying 2.19 percent to $21.31 at the time of publication Thursday.

Related Links:

4 Cannabis Stocks In Uptrends This Week

The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Latest Ratings for CARA

DateFirmActionFromTo
Sep 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Sep 2018JefferiesInitiates Coverage OnBuy
Aug 2018Canaccord GenuityMaintainsBuyBuy

View More Analyst Ratings for CARA
View the Latest Analyst Ratings

Posted-In: Jefferies Matthew AndrewsAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

 

Related Articles (CARA)

View Comments and Join the Discussion!

Mid-Day Market Update: Crude Oil Down Over 2%; Progenics Pharmaceuticals Shares Plunge

South Korea Might Be The First Country To Activate The Mass-Market Adoption Of Blockchain Technology